ZYUS Life Sciences Corporation remains steady amid recent announcements and market activity.
ZYUS Life Sciences Corporation (ZYUS.V) has maintained its stock price this week, closing at C$0.60 on Thursday. The company recently announced key updates regarding its clinical trial results and governance changes, which could influence investor sentiment moving forward.
Investor takeaway: With stable price action and positive developments in clinical trials, ZYUS Life Sciences Corporation presents a cautious opportunity for investors interested in the healthcare sector.
Advertisement
ZYUS Life Sciences Corporation
ZYUS.V
ZYUS.V
ZYUS Life Sciences Corporation
WealthAwesomeMarket cap
$48.31M
52W high
$0.75
52W low
$0.37
1W change
+0.00%
Beta
0.16
Analyst Price Targets
Based on analyst covering ZYUS · as of Sep 17, 2026
Wall Street analysts forecast ZYUS stock price to rise 150.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$1.50
+150.0% Upside
Current Price
C$0.60
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ZYUS's historical volatility
30-Day Vol
173.3%
Annualized
90-Day Vol
128.3%
Annualized
Trend (90d)
-6.9%
Annualized drift
90d Mean
C$0.59
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.60 | C$0.33 – C$1.08 |
| 60 trading days | C$0.59 | C$0.25 – C$1.37 |
| 90 trading days | C$0.59 | C$0.21 – C$1.65 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
C$0.60 closing price with a 20% increase over the last month.
ZYUS Life Sciences has seen a notable increase of 20% in its stock price over the past month, indicating potential recovery or growing investor interest.
Bull case
Analysts are optimistic, with an average target of C$1.50, suggesting significant upside potential from current levels. The planned release of Phase 2a clinical trial results may further boost investor confidence.
Bear case
Despite the positive outlook, the company faces challenges, including a negative return on equity and a profit margin of 0.0%. Investors should be aware of the risks associated with the company's financial health.
Recent Company News
On September 25, ZYUS Life Sciences Corporation announced the planned release date for its Phase 2a clinical trial results, along with the results from its Annual General Meeting and a change in the Audit Committee Chair. These developments are important as they could provide insights into the company's operational direction and clinical progress.
Advertisement
Technical Picture
ZYUS Life Sciences is currently trading at C$0.60, which is above its 50-day moving average of C$0.53 and its 200-day moving average of C$0.56. The stock has a 52-week range of C$0.37 to C$0.75, placing it at 61% of its range. The beta of 0.16 indicates low volatility compared to the broader market. The recent trading volume of 22,600 shares is significantly higher than the 20-day average volume of 12,427 shares, suggesting increased interest in the stock.
Insider Activity
No recent insider activity has been reported for ZYUS Life Sciences Corporation, which may indicate stability in the company's management and ownership structure.
Price Action
As of the last close, ZYUS Life Sciences Corporation remains unchanged at C$0.60, reflecting a steady performance amid recent announcements.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
